RAPAMUNE

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug RAPAMUNE contains one active pharmaceutical ingredient (API):

1 Sirolimus UNII W36ZG6FT64 - SIROLIMUS

Sirolimus inhibits T-cell activation induced by most stimuli, by blocking calcium-dependent and calcium-independent intracellular signal transduction. Studies demonstrated that its effects are mediated by a mechanism that is different from that of ciclosporin, tacrolimus, and other immunosuppressive agents. Read about Sirolimus

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
RAPAMUNE Coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AH01	Sirolimus	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AH Mammalian target of rapamycin (mTOR) kinase inhibitors
Discover more medicines within L04AH01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 6436R, 6437T, 6457W, 8724E, 8725F, 8833X, 8984W, 9548M, 9549N, 9550P, 9747B, 9748C
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 522720020083817, 522720020083917
Country: CA	Health Products and Food Branch	Identifier(s): 02243237, 02247111
Country: EE	Ravimiamet	Identifier(s): 1012857, 1107739, 1107740, 1132490, 1132502, 1484647, 1484658, 1849787
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 01171001, 01171008, 01171009, 01171013
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 003353, 011548, 467514
Country: FR	Base de données publique des médicaments	Identifier(s): 61752409, 64597615, 65164182, 69171174
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 184017, 40911, 40916, 45648
Country: HK	Department of Health Drug Office	Identifier(s): 50220, 61049
Country: IE	Health Products Regulatory Authority	Identifier(s): 88340, 88343, 88415
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 4405, 4804
Country: IT	Agenzia del Farmaco	Identifier(s): 035120017, 035120068, 035120070, 035120094, 035120106, 035120118, 035120120
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1004272, 1007508, 1010323, 1014606, 1014607, 1056075, 1056076
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 099M2000, 125M2001
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 57908, 63746, 68802
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 10241, 11283, 14308, 9407
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100103636, 100112747, 100127690, 100235970
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W65025001
Country: SG	Health Sciences Authority	Identifier(s): 11964P, 12034P, 12647P
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 8013131H, 8063111H
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8681308015099, 8681308015167, 8681308127457, 8681308127464, 8681308597472
Country: US	FDA, National Drug Code	Identifier(s): 0008-1030, 0008-1040, 0008-1041, 0008-1042
Country: ZA	Health Products Regulatory Authority	Identifier(s): 35/34/0009, A38/34/0440